Aclaris Therapeutics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share
August 11, 2016 7:05 AM EDTAclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
... More